Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Affymax
With that in mind, let's take a closer look at Affymax's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Palo Alto, Calif. (2001)|
|Market Cap||$452.2 million|
|Trailing-12-Month Revenue||$47.7 million|
CEO John Orwin
CFO Herbert Cross
|Cash/Debt||$98.5 million / $0.0 million|
Johnson & Johnson
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 24% of the 132 members who have rated Affymax believe the stock will underperform the S&P 500 going forward.
I suspect the share price and the drug sales of Omontys will be rather ANEMIC in the ... short run.
Overall ... approval of Affymax's injectable drug Omontys, once [monthly] for those with kidney disease, should be lower cost than the monopoly drugs currently on the market.
The rise in share price prior to the announcement pretty much values Affymax [fairly] for now, especially with the split that will go to [Takeda Pharmaceutical]. ... The road to production is generally long and those investing in FDA catalyst drugs are generally not loyal.
If you want to retire rich, you need to protect your portfolio from any undue risk. Luckily, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so access it now.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
The Nasdaq's 5 Most Hated Stocks
The Nasdaq hasn't had a down month this year, but that's not stopping skeptics from piling onto these five companies.
3 Reasons Investors Are Scared of Biotech Stocks
There's more than one way to see monster drops.
5 of Last Week's Biggest Losers
These five companies went the wrong way this past week.